{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T03:05:08Z","timestamp":1763348708914,"version":"3.38.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jfo.2024.104380","type":"journal-article","created":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T07:51:19Z","timestamp":1733903479000},"page":"104380","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Topical 5-fluorouracil 1% as first-line therapy for giant ocular surface squamous neoplasia"],"prefix":"10.1016","volume":"48","author":[{"given":"R.","family":"Alvarado-Villacorta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Ramos-Betancourt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.H.","family":"Davila-Alquisiras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.A.","family":"Vazquez-Romo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfo.2024.104380_bib0255","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.ophtha.2004.02.013","article-title":"Clinical survey of 1643 melanocytic and nonmelanocytic conjunctival tumors","volume":"111","author":"Shields","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2024.104380_bib0260","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.jtos.2020.07.011","article-title":"Whole exome profiling and mutational analysis of ocular surface squamous neoplasia","volume":"18","author":"Ramos-Betancourt","year":"2020","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jfo.2024.104380_bib0265","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/17469899.2017.1263567","article-title":"Diagnosis and medical management of ocular surface squamous neoplasia","volume":"12","author":"Sayed-Ahmed","year":"2017","journal-title":"Expert Rev Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104380_bib0270","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/s41433-018-0058-7","article-title":"Proposal for a new classification for ocular surface squamous neoplasia","volume":"32","author":"Meel","year":"2018","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.jfo.2024.104380_bib0275","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1136\/bjo.2009.168294","article-title":"Treatment of ocular surface squamous neoplasia with mitomycin C","volume":"94","author":"Gupta","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104380_bib0280","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4103\/ijo.IJO_590_17","article-title":"Topical chemotherapy for giant ocular surface squamous neoplasia of the conjunctiva and cornea: is surgery necessary?","volume":"66","author":"Chaugule","year":"2018","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104380_bib0285","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40662-019-0150-5","article-title":"Update on pharmacotherapy for ocular surface squamous neoplasia","volume":"6","author":"Al Bayyat","year":"2019","journal-title":"Eye Vis (Lond)"},{"key":"10.1016\/j.jfo.2024.104380_bib0290","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40123-019-00225-w","article-title":"Management issues in conjunctival tumours: ocular surface squamous neoplasia","volume":"9","author":"Cohen","year":"2020","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.jfo.2024.104380_bib0295","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.ophtha.2013.11.017","article-title":"Surgical versus medical treatment of ocular surface squamous neoplasia: a comparison of recurrences and complications","volume":"121","author":"Nanji","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2024.104380_bib0300","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s40123-018-0140-z","article-title":"Clinical management of ocular surface squamous neoplasia: a review of the current evidence","volume":"7","author":"Cicinelli","year":"2018","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.jfo.2024.104380_bib0305","doi-asserted-by":"crossref","first-page":"e000842","DOI":"10.1136\/bmjophth-2021-000842","article-title":"Management of ocular surface squamous neoplasia: Bowman Club Lecture 2021","volume":"6","author":"Alvarez","year":"2021","journal-title":"BMJ Open Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104380_bib0310","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/ceo.12184","article-title":"Long-term outcomes after adjunctive topical 5-flurouracil or mitomycin C for the treatment of surgically excised, localized ocular surface squamous neoplasia","volume":"42","author":"Bahrami","year":"2014","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104380_bib0315","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1016\/j.ophtha.2010.03.052","article-title":"Subconjunctival\/perilesional recombinant interferon \u03b12b for ocular surface squamous neoplasia: a 10-year review","volume":"117","author":"Karp","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2024.104380_bib0320","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1097\/01.ico.0000240088.38631.46","article-title":"Short-term mitomycin C followed by long-term interferon alpha2beta for conjunctiva-cornea intraepithelial neoplasia","volume":"25","author":"Huerva","year":"2006","journal-title":"Cornea"},{"key":"10.1016\/j.jfo.2024.104380_bib0325","doi-asserted-by":"crossref","first-page":"131","DOI":"10.5935\/0004-2749.20170032","article-title":"Adjuvant treatment or primary topical monotherapy for ocular surface squamous neoplasia: a systematic review","volume":"80","author":"Viani","year":"2017","journal-title":"Arq Bras Oftalmol"},{"key":"10.1016\/j.jfo.2024.104380_bib0330","doi-asserted-by":"crossref","first-page":"563","DOI":"10.4103\/ijo.IJO_1665_20","article-title":"Primary treatment of ocular surface squamous neoplasia with topical interferon alpha-2b: comparative analysis of outcomes based on original tumor configuration","volume":"69","author":"Shields","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104380_bib0335","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/bjo.2010.183244","article-title":"Topical 1% 5-fluorouracil in ocular surface squamous neoplasia: a long-term safety study","volume":"95","author":"Parrozzani","year":"2011","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104380_bib0340","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.ophtha.2016.02.034","article-title":"Topical 5-fluorouracil 1% as primary treatment for ocular surface squamous neoplasia","volume":"123","author":"Joag","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2024.104380_bib0345","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1136\/bjophthalmol-2016-309219","article-title":"Topical 1% 5-fluoruracil as a sole treatment of corneoconjunctival ocular surface squamous neoplasia: long-term study","volume":"101","author":"Parrozzani","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104380_bib0350","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ajo.2018.11.007","article-title":"Comparison of topical 5-fluorouracil and interferon alfa-2b as primary treatment modalities for ocular surface squamous neoplasia","volume":"199","author":"Venkateswaran","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104380_bib0355","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jtos.2022.12.002","article-title":"Topical 1% 5-fluorouracil eye drops as primary treatment for ocular surface squamous neoplasia: long-term follow-up study","volume":"27","author":"Wylegala","year":"2023","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jfo.2024.104380_bib0360","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/ceo.12377","article-title":"Management of diffuse ocular surface squamous neoplasia: efficacy and complications of topical chemotherapy","volume":"43","author":"Rudkin","year":"2015","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104380_bib0365","article-title":"Resolution of giant ocular surface squamous neoplasia with topical 5-fuorouracil 1","volume":"7","author":"Mohamed-Noriega","year":"2019","journal-title":"SAGE Open Med Case Rep"},{"key":"10.1016\/j.jfo.2024.104380_bib0370","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jfo.2018.12.019","article-title":"Complete regression of a giant conjunctival intraepithelial neoplasia using 5-fluorouracil","volume":"42","author":"Garc\u00eda de Oteyza","year":"2019","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.jfo.2024.104380_bib0375","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jfo.2018.11.005","article-title":"Rapid resolution of squamous cell carcinoma with topical chemotherapy","volume":"42","author":"Vazquez-Romo","year":"2019","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.jfo.2024.104380_bib0380","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.ophtha.2011.11.035","article-title":"Giant ocular surface squamous neoplasia managed with interferon alpha-2b as immunotherapy or immunoreduction","volume":"119","author":"Kim","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2024.104380_bib0385","doi-asserted-by":"crossref","first-page":"936","DOI":"10.4103\/ijo.IJO_251_17","article-title":"Clinicodemographic profile and treatment outcome in patients of ocular surface squamous neoplasia","volume":"65","author":"Meel","year":"2017","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104380_bib0390","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1136\/bjo.2009.160820","article-title":"Topical chemotherapy for ocular surface squamous neoplasia: current status","volume":"94","author":"Sepulveda","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104380_bib0395","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF00166683","article-title":"Topical application of 5-fluorouracil in premalignant lesions of cornea, conjunctiva and eyelid","volume":"64","author":"de Keizer","year":"1986","journal-title":"Doc Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104380_bib0400","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2147\/OPTH.S9709","article-title":"5-fluorouracil for the treatment of intraepithelial neoplasia and squamous cell carcinoma of the conjunctiva, and cornea","volume":"4","author":"Al-Barrag","year":"2010","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104380_bib0405","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/08820538.2019.1648691","article-title":"Interferon alfa 2b for ocular surface squamous neoplasia: factors influencing the treatment response","volume":"34","author":"Kaliki","year":"2019","journal-title":"Semin Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104380_bib0410","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/ceo.13382","article-title":"Extending far and wide: the role of biopsy and staging in the management of ocular surface squamous neoplasia","volume":"47","author":"Polski","year":"2019","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104380_bib0415","doi-asserted-by":"crossref","first-page":"393","DOI":"10.4103\/0301-4738.185620","article-title":"Interferon alpha-2b in giant ocular surface squamous neoplasia","volume":"64","author":"Hernandez-Bogantes","year":"2016","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104380_bib0420","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ajo.2009.07.026","article-title":"Ocular surface squamous neoplasia after corneal graft","volume":"149","author":"Ramasubramanian","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104380_bib0425","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bcr-2020-240994","article-title":"Topical interferon alpha-2b for a giant ocular surface squamous neoplasia: 7 years of follow-up after complete remission","volume":"14","author":"Galvis","year":"2021","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jfo.2024.104380_bib0430","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/IOP.0b013e318203d605","article-title":"Ocular surface squamous neoplasia (squamous cell carcinoma) of the socket: management of extensive tumors with interferon","volume":"27","author":"Shields","year":"2011","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.jfo.2024.104380_bib0435","doi-asserted-by":"crossref","first-page":"423","DOI":"10.4103\/2008-322X.150811","article-title":"Topical interferon alpha-2b for treatment of noninvasive ocular surface squamous neoplasia with 360\u030a limbal involvement","volume":"9","author":"Zarei-Ghanavati","year":"2014","journal-title":"J Ophthalmic Vis Res"},{"key":"10.1016\/j.jfo.2024.104380_bib0440","doi-asserted-by":"crossref","first-page":"S374","DOI":"10.1097\/ICL.0000000000000473","article-title":"Giant ocular surface squamous neoplasia wrapping the whole cornea","volume":"44","author":"Dhiman","year":"2018","journal-title":"Eye Contact Lens"},{"key":"10.1016\/j.jfo.2024.104380_bib0445","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1159\/000486339","article-title":"Widespread ocular surface squamous neoplasia treated with topical interferon alpha-2b","volume":"4","author":"Patel","year":"2018","journal-title":"Ocul Oncol Pathol"},{"key":"10.1016\/j.jfo.2024.104380_bib0450","doi-asserted-by":"crossref","first-page":"62","DOI":"10.22336\/rjo.2020.12","article-title":"Relapsed ocular squamous surface neoplasia treated with topical interferon alfa-2b","volume":"64","author":"Rocha-de-Lossada","year":"2020","journal-title":"Rom J Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104380_bib0455","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0002-9394(02)01400-9","article-title":"Topical mitomycin C for extensive, recurrent conjunctival-corneal squamous cell carcinoma","volume":"133","author":"Shields","year":"2002","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104380_bib0460","first-page":"1","article-title":"Xeroderma pigmentosum with bilateral ocular surface squamous neoplasia and review of the literature","volume":"2016","author":"Kalamkar","year":"2016","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jfo.2024.104380_bib0465","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/IIO.0000000000000050","article-title":"Ocular surface squamous neoplasia: evidence for topical chemotherapy","volume":"55","author":"Pe\u2019er","year":"2015","journal-title":"Int Ophthalmol Clin"},{"key":"10.1016\/j.jfo.2024.104380_bib0470","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ophtha.2011.08.005","article-title":"Squamous carcinoma and dysplasia of the conjunctiva and cornea: an analysis of 101 cases","volume":"119","author":"Yousef","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2024.104380_bib0475","doi-asserted-by":"crossref","first-page":"702","DOI":"10.4103\/0301-4738.195010","article-title":"Recombinant interferon alpha 2b for ocular surface squamous neoplasia: an efficient and cost-effective treatment modality in Asian Indian patients","volume":"64","author":"Kaliki","year":"2016","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104380_bib0480","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jtos.2015.02.001","article-title":"High-resolution optical coherence tomography as an adjunctive tool in the diagnosis of corneal and conjunctival pathology","volume":"13","author":"Nanji","year":"2015","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jfo.2024.104380_bib0485","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40662-019-0152-3","article-title":"Utility of high-resolution anterior segment optical coherence tomography in the diagnosis and management of sub-clinical ocular surface squamous neoplasia","volume":"6","author":"Tran","year":"2019","journal-title":"Eye Vis (Lond)"},{"key":"10.1016\/j.jfo.2024.104380_bib0490","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0161-6420(97)30287-5","article-title":"Late recurrences and the necessity for long-term follow-up in corneal and conjunctival intraepithelial neoplasia","volume":"104","author":"Tabin","year":"1997","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2024.104380_bib0495","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/01.ico.0000138834.42489.ba","article-title":"Ocular surface squamous neoplasia: a standard of care survey","volume":"24","author":"Stone","year":"2005","journal-title":"Cornea"},{"key":"10.1016\/j.jfo.2024.104380_bib0500","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1097\/ICO.0b013e3182a6ea6c","article-title":"Ocular surface squamous neoplasia: a survey of changes in the standard of care from 2003 to 2012","volume":"32","author":"Adler","year":"2013","journal-title":"Cornea"}],"container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551224003255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551224003255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T09:23:12Z","timestamp":1740993792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0181551224003255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0181551224003255"],"URL":"https:\/\/doi.org\/10.1016\/j.jfo.2024.104380","relation":{},"ISSN":["0181-5512"],"issn-type":[{"type":"print","value":"0181-5512"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Topical 5-fluorouracil 1% as first-line therapy for giant ocular surface squamous neoplasia","name":"articletitle","label":"Article Title"},{"value":"Journal Fran\u00e7ais d'Ophtalmologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfo.2024.104380","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104380"}}